Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium (Nasdaq: COLL) announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
Rhea-AI Summary
Collegium (Nasdaq: COLL) announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
The session is scheduled for Wednesday, June 3, 2026, at 1:20 p.m. ET, with a live webcast and 90-day replay on the company’s investor website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – COLL
On May 27, the day this news came out, COLL closed 0.30% below the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Conference year
- 2026
- Jefferies Global Healthcare Conference
- Fireside chat date
- June 3, 2026
- Jefferies Global Healthcare Conference
- Fireside chat time
- 1:20 p.m. ET
- Jefferies Global Healthcare Conference session
- Webcast archive period
- 90 days
- Replay available on company website
Historical Context
-
Closed AZSTARYS acquisition, increased 2026 guidance and outlined synergy targets.
-
Reported Q1 2026 results with 9% YoY revenue growth and reaffirmed guidance.
-
Announced timing of Q1 2026 results and related conference call details.
-
Disclosed participation in Needham and Piper Sandler investor conferences.
-
Announced plan to acquire AZSTARYS with expectations for EBITDA accretion.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.
Details of the event are as follows:
Fireside Chat Date and Time: Wednesday, June 3, 2026, at 1:20 p.m. ET
New York, NY
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions.
With a portfolio of differentiated ADHD medications, anchored by JORNAY PM® (methylphenidate HCl) and AZSTARYS® (serdexmethylphenidate and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives. For more information, please visit collegiumpharma.com or find us on LinkedIn.
Investor Contact:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.